Evidence map›Paper›PMID 38619056›Full record

ArticleHuman vaccines & immunotherapeutics2024

Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China.

Aodi Huang, Xia Xu, Lin Tang, Lifang Huang, Jun Li, Xue Zhang, Jiajie Liu, Yang Zhou, Bingling Zhang, Lei Wang and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Aodi HuangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Xia XuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Lin TangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Lifang HuangDepartment of National Immunization Programe, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China.
Jun LiDepartment of National Immunization Programe, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, China.
Xue ZhangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Jiajie LiuDepartment of National Immunization Programe, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China.
Yang ZhouDepartment of National Immunization Programe, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Bingling ZhangDepartment of National Immunization Programe, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China.
Lei WangDepartment of National Immunization Programe, Hubei Provincial Center for Disease Control and Prevention, Wuhan, China.
Qian ZhangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zemei ZhouNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Yu WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Xiaoqi WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Qianqian LiuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Siyu LiuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zundong YinNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Fuzhen WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Chinese Center For Disease Control and Prevention · CNCenter for Disease Control · TWGansu Provincial Center for Disease Control and Prevention · CNHenan Provincial Center for Disease Control and Prevention · CNHubei Provincial Center for Disease Control and Prevention · CNSichuan Center for Disease Control and Prevention · CNZhejiang Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease. Currently, no hexavalent vaccines have been approved for use in China. Evidence of parental acceptance and interest in hexavalent vaccines can help policy makers and manufacturers make decisions about entering the vaccine market and the immunization program in China. We measured parental acceptance and willingness-to-pay (WTP) for a hexavalent vaccine to provide such evidence. We conducted a cross-sectional survey of children's caregivers in 16 vaccination clinics in seven cities in China and obtained information on socio-demographics, knowledge of disease, confidence in vaccines, previous vaccination experience, and acceptance of and WTP for hexavalent vaccine. Multivariate logistic regression was used to determine factors influencing acceptance, and multivariate tobit regression was used to identify factors impacting WTP. Between April 28 and June 30, 2023, a total of 581 parents of children aged 0-6 years participated in the survey; 435 (74.87%, 95% CI:71.3%-78.4%) parents indicated acceptance of hexavalent vaccine. Residence location, parents' education level, experience paying for vaccination, and disease knowledge scores were key factors affecting parents' choices for vaccination. Mean (SD) and median (IQR) willingness to pay for full 4-dose course vaccination were 2266.66 (1177.1) CNY and 2400 (1600-2800) CNY. Children's age (

Indexed as

Diphtheria-Tetanus-Pertussis VaccineHaemophilus influenzae type bHaemophilus VaccinesHepatitis B VaccinesChildChinaCross-Sectional StudiesHumansVaccines, Combineddiphtheria-tetanus-acellular pertussis-Hib-hepatitis B vaccineDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesHepatitis B VaccinesVaccines, Combinedcombination vaccineHexavalent vaccinepayment card methodvaccine acceptancewillingness to pay

Identifiers

PMID38619056
PMCPMC11020590
OpenAlexW4394812672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.